Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer

Reuters11-11

<a href="https://laohu8.com/S/BOLD">Boundless Bio</a> Unveils New Therapies Targeting ecDNA-Driven Cancer

Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies (ecDTx). The company highlights the significant unmet medical need for therapies targeting oncogene amplified cancers, which are generally unresponsive to existing targeted and immunotherapies. Boundless Bio's approach leverages extrachromosomal DNA (ecDNA), identified as a key driver of oncogene amplification in cancer. The presentation outlines the company's clinical-stage candidates, including BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, both being evaluated in the POTENTIATE clinical trial. Additionally, BBI-940, an oral Kinesin degrader, is expected to begin clinical trials in the first half of 2026. According to the company, approximately 25% of cancer patients have amplified oncogenes, with about half of high-copy number amplifications occurring on ecDNA. There are currently no approved therapies for these cancers, except for HER2 inhibitors. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582801089?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582801089","market":"us","top_or_hot":-1,"title":"Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BOLD\">Boundless Bio</a> Unveils New Therapies Targeting ecDNA-Driven Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies (ecDTx). The company highlights the significant unmet medical need for therapies targeting oncogene amplified cancers, which are generally unresponsive to existing targeted and immunotherapies. Boundless Bio's approach leverages extrachromosomal DNA (ecDNA), identified as a key driver of oncogene amplification in cancer. The presentation outlines the company's clinical-stage candidates, including BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, both being evaluated in the POTENTIATE clinical trial. Additionally, BBI-940, an oral Kinesin degrader, is expected to begin clinical trials in the first half of 2026. According to the company, approximately 25% of cancer patients have amplified oncogenes, with about half of high-copy number amplifications occurring on ecDNA. There are currently no approved therapies for these cancers, except for HER2 inhibitors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 02:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BOLD\">Boundless Bio</a> Unveils New Therapies Targeting ecDNA-Driven Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies (ecDTx). The company highlights the significant unmet medical need for therapies targeting oncogene amplified cancers, which are generally unresponsive to existing targeted and immunotherapies. Boundless Bio's approach leverages extrachromosomal DNA (ecDNA), identified as a key driver of oncogene amplification in cancer. The presentation outlines the company's clinical-stage candidates, including BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, both being evaluated in the POTENTIATE clinical trial. Additionally, BBI-940, an oral Kinesin degrader, is expected to begin clinical trials in the first half of 2026. According to the company, approximately 25% of cancer patients have amplified oncogenes, with about half of high-copy number amplifications occurring on ecDNA. There are currently no approved therapies for these cancers, except for HER2 inhibitors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOLD","symbol_name":"Boundless Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7ppXqg:1","article_id":"2582801089","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582801089","pubTimestamp":1762800661,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies . The company highlights the significant unmet medical need for therapies targeting oncogene amplified cancers, which are generally unresponsive to existing targeted and immunotherapies. Boundless Bio's approach leverages extrachromosomal DNA , identified as a key driver of oncogene amplification in cancer. The presentation outlines the company's clinical-stage candidates, including BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, both being evaluated in the POTENTIATE clinical trial. Additionally, BBI-940, an oral Kinesin degrader, is expected to begin clinical trials in the first half of 2026. According to the company, approximately 25% of cancer patients have amplified oncogenes, with about half of high-copy number amplifications occurring on ecDNA. There are currently no approved therapies for these cancers, except for H","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BOLD":"Boundless Bio, Inc.","BK4139":"生物科技"},"translate_title":"Boundless Bio推出针对ecDNA驱动癌症的新疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOLD":0.9},"content_text":"Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer\n    \n\n        Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies (ecDTx). The company highlights the significant unmet medical need for therapies targeting oncogene amplified cancers, which are generally unresponsive to existing targeted and immunotherapies. Boundless Bio's approach leverages extrachromosomal DNA (ecDNA), identified as a key driver of oncogene amplification in cancer. The presentation outlines the company's clinical-stage candidates, including BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, both being evaluated in the POTENTIATE clinical trial. Additionally, BBI-940, an oral Kinesin degrader, is expected to begin clinical trials in the first half of 2026. According to the company, approximately 25% of cancer patients have amplified oncogenes, with about half of high-copy number amplifications occurring on ecDNA. There are currently no approved therapies for these cancers, except for HER2 inhibitors. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582801089","isCrawlerRequest":true}